The drug portal FASS has four million visitors every month, of which just over half are healthcare personnel. In February, the new service will be launched, which shows detailed information on residual drugs.
- We hope it will be a minor problem, both for healthcare, pharmacies and we hope it provides a security for patients, says Bengt Mattson at the pharmaceutical company LIF.
- It is good that the information becomes more easily accessible, says Mikael Hoffman at the Swedish Medical Association.
However, LIF says that despite the new service, it will take several years to rectify the shortage of medicines. The Swedish Medical Association also addresses the problem:
- Information is good, but it does not solve the basic problem of residual drugs, says Heidi Stensmyren, chairman of the Swedish Medical Association.